Last reviewed · How we verify
wIPV-wIPV-bOPV vaccination schedule
The wIPV-wIPV-bOPV vaccine induces immune responses against the poliovirus types 1, 2, and 3.
The wIPV-wIPV-bOPV vaccine induces immune responses against the poliovirus types 1, 2, and 3. Used for Prevention of poliomyelitis.
At a glance
| Generic name | wIPV-wIPV-bOPV vaccination schedule |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | inactivated vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the administration of inactivated poliovirus particles, which stimulate the production of antibodies and immune cells that can recognize and neutralize the poliovirus. The vaccine is designed to provide long-term protection against poliomyelitis.
Approved indications
- Prevention of poliomyelitis
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants (PHASE3)
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- wIPV-wIPV-bOPV vaccination schedule CI brief — competitive landscape report
- wIPV-wIPV-bOPV vaccination schedule updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI